Mode
Text Size
Log in / Sign up
N/A Completed N=169 Randomized Single-blind Treatment

Restylane Perlane Lidocaine for Correction of Midface Volume Deficit and/or Midface Contour Deficiency

Midface Volume Deficit
Source: ClinicalTrials.gov NCT03097783 ↗
Enrolled (actual)
169
Serious AEs
0.0%
Results posted
Jul 2021
Primary outcomePrimary: Percent Responders With 1 Point Improvement on the Medicis Midface Volume Scale — 67; 8 Participants

Summary

This is a randomized, multi-center, evaluator-blinded, no-treatment controlled study to evaluate the efficacy and safety of Restylane Perlane Lidocaine for correction of Midface Volume Deficit and/or Midface Contour Deficiency.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent Responders With 1 Point Improvement on the Medicis Midface Volume Scale
67; 8

Eligibility Criteria

Inclusion Criteria

  • Signed informed consent
  • Men or women aged 18 years of age or older of Chinese origin
  • Subjects willing to abstain from any other facial plastic surgical or cosmetic procedures below the level of the lower orbital rim for the duration of the study
  • Subjects seeking augmentation therapy for the midface
  • MMVS score of 2, 3 or 4 on each side of the face as assessed by the blinded evaluator

Exclusion Criteria

  • Known/previous allergy or hypersensitivity to any injectable HA gel/local anaesthetics, e.g.lidocaine or other amide-type anaesthetics.
  • Previous surgery or tattoo in the area to be treated
  • Previous tissue augmentation therapy or contouring with any permanent (non-biodegradable) or semi-permanent filler, autologous fat, lifting threads or permanent implant below the level of the lower orbital rim.
  • Previous use of any hyaluronic acid based or collagen based biodegradable facial tissue augmentation therapy below the level of the lower orbital rim or neurotoxin within 12 months before treatment.
  • Scars or deformities, active skin disease, inflammation or related conditions, such as infection, perioral dermatitis, seborrheic eczema, rosacea, acne psoriasis and herpes zoster near or in the area to be treated.
  • Other condition preventing the subject from entering the study in the Investigator's opinion.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03097783). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search